The impact that spin-outs ultimately create is core to our mission and our impact-maturity matrix is the key tool we have developed to assess and combine the potential social and economic benefits of all the innovations we support.

From the minute an innovation is accepted for a spin-out, we work with you to ensure that the benefits created by the spin-out can be disseminated as widely as possible. When the decision is made to spin out, the potential impact is re-evaluated as the pathway an innovation takes can vastly change its outcome.

  • More time investment from the commercial management team, and
  • Larger financial resources through the Ploughshare Acceleration Fund and other means

 

 

supportive

ploughshare table

[Our ownership] allows us to engage with industry to negotiate licence deals and create spin-out companies – ultimately levering government technologies for the good of society.’

Impact report, 2021

Case Study – Esroe

Mission and strategy

Presymptom Health is a pioneering medtech business that creates diagnostic tests to detect illnesses earlier to help save lives. Their tests have a number of unique benefits:

  • Identifies those at risk of deterioration before symptoms present, allowing clinicians to discharge patients with confidence
  • Enhances triaging of patients to the appropriate level of care and acute monitoring
  • Identifies the subsets of patients most in need of investigational and/or high risk/cost therapies

Ploughshare’s help:

Hetti Barkworth-Nanton, Ploughshare’s CEO, said:

“Ploughshare awarded Presympton Health £200,000 pre-seed funding and a further £265,000 at the seed round to fund the first phase for developing a prototype diagnostic test. Using Ploughshare’s impact-maturity matrix, it saw how much potential this technology has and saw the value in accelerating its development funding.”

Spin-out impact:

Presymptom’s technology has the potential to be directly relevant for Covid-19 patients, which will provide vital and lifesaving information. Additionally, Presymptom’s predictive test for sepsis has the ability to save millions of lives each year.

“We were an integral and vital part of the founding team; helping devise strategy, draft the business plan and close the seed-investment round with their investors, UKI2S”

Mark Gostock, VP Commercialisation (Health & Wellbeing)

“Our Commercialisation Manager led us through the complex journey and it always helped to discuss things openly and to be challenged by them”

Iain Miller, CEO, Presymptom Health

decision to spinnout

Deciding to spin-out

Having assessed the innovation against its IP position, market and potential impact, we will decide together with you, your team and your government department whether a spin-out is a viable option. If it is, all the inventors of the innovation team will have decisions to make about how they want to be involved in the spin-out and these are discussed in the next section.

Back

Further reading

PLOUGHSHARE IMPACT REPORT 2021
THE MACKINTOSH REPORT APRIL 2021
PLOUGHSHARE PRESS RELEASE

Continue your journey

Spin-out preparation and pathways

Ready to Spinout?

Are you an investor looking for your next venture or an inventor looking to make your idea real. Fill out our form and one of our team will contact you.

  • This field is for validation purposes and should be left unchanged.

Quick Navigation

About the Playbook

Build out a commercial business backed by unique government led innovation, with the Ploughshare Spinout Playbook